A Harvard professor’s deal with private equity could save clinical research

The Trump administration’s widespread cuts to federal funding for scientific and clinical research has adversely impacted hundreds of universities across the country.

In the absence of reliable support from the federal government, where can clinical research teams look?

Could the answer be private equity?

Professor Gökhan S Hotamisligil, the James Stevens Simmons Professor of Genetics and Metabolism at Harvard T.H. Chan School, speaks with managing editor Jack O’Brien about the unique collaboration between Harvard and İş Private Equity, a Turkish financial organization which has pledged $39 million to fund the work of the professor and his clinical research team for a decade.

As he notes, this doesn’t make up for the lack of federal funding – nothing quite can – but it offers a much-needed lifeline during a turbulent time.

For our Trends segment, we’re previewing the Q2 earnings season for pharma companies – including what trends may impact their financial releases in the coming weeks. 

Music: “Deep Reflection” by DP and Triple Scoop Music.

Check us out at: mmm-online.com

Follow us:

YouTube: @MMM-online

TikTok: @MMMnews

Instagram: @MMMnewsonline

Twitter/X: @MMMnews

LinkedIn: MM+M

To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

Music: “Deep Reflection” by DP and Triple Scoop Music.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.